Increasing HIV-drug resistance in low- and middle income countries


In a systematic review of 358 datasets representing 56,044 adult patients in 63 countries the pretreatment drug resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was estimated. NNRTI resistance was more prevalent in more recent studies compared to older studies in all regions. In 2016 the prevalence of NNRTI resistance was estimated to be 11.0 % in southern Africa, 10.1 % in eastern Africa, 7.2 % in western and central Africa, 9.4 % in Latin America and the Caribbean and 11 % in Asia.'

Gupta et al. Lancet Infect Dis 2018;18:346–355

Comment: The change from NNRTIs to dolutegravir as part of first line therapy in the WHO guidelines for low and middle income countries seems to be a necessary step.